ART FOR ART PREVENTION. Introduction of ongoing or planned trials
|
|
- Everett Lawrence
- 5 years ago
- Views:
Transcription
1 ART FOR ART PREVENTION Introduction of ongoing or planned trials François Dabis, MD, PhD for WHO Department of HIV/AIDS Geneva - November 3, 2009
2 ART FOR ART PREVENTION as of November 2009 Descriptive epidemiology of «who does what» Except modelling
3 ART FOR ART PREVENTION as of November 2009 Who does what Acknowledgements M. Cohen, C. Dieffenbach, W. El-Sadr, S. Fidler, R. Gray, M-L. Newell, J. Montaner, S. Reynolds, M. Sweat, J. Weber, B. Williams
4 Phase I: Pilot projects Acceptability of testing Acceptability of treatment Compliance with treatment Minimal side effects Make sure that we do not create stigma Check that we get viral load suppression Measure residual transmission Check for viral rebound Monitor drug resistance Consider cost and delivery
5 NIMH Project Accept HPTN 043 Impact of Community-Based Provision of VCT Thailand, rural Tanzania, very rural Soweto, Gauteng, South Africa, urban Vulindlela, Kwazulu Natal, South Africa, rural Zimbabwe, very rural Comparing two VCT approaches during 2.5 years: standard (clinic-based) versus community-based (mobile with post-test support services) Behavioral and biological assessment at community level
6 CTN0032: HIV rapid testing & counselling in drug abuse treatment programs in the USA A randomized controlled trial of the relative effectiveness of three HIV testing strategies on increasing receipt of test results and reducing HIV sexual risk behaviors An adaptation to STD clinics planned
7 Long-term follow-up of serodiscordant couples in the ART era Rakai, Uganda: prospective cohort
8 Population effect of Anti-retroviral therapy to Reduce HIV Transmission (PopART) A step-by-step research program in Uganda (Masaka) and Zambia (ZAMBART) PopART feasibility Acceptability, feasibility, cost-effectiveness and safety of the Universal Test and Treat strategy
9 Treatment as Prevention (TasP) A step-by-step research program in South Africa TasP «zero» How to provide universal testing - How to provide effective universal ART - Determining origin of new infections - Documenting ARV resistance patterns
10 TasP QuickTime et un décompresseur TIFF (non compressé) sont requis pour visionner cette image.
11 Phase II: Randomized controlled trials or step-wise interventions Monitor all outcomes investigated in phase I studies And measure changes in incidence of HIV and TB at a population level
12 HPTN 052 Selected Research Goals Discordant couples study randomized to immediate or deferred therapy to determine : Impact of early ART on HIV disease progression (between 250 and 550 CD4 cells) Efficacy of ART in preventing HIV transmission
13 HPTN 052 an RCT 1,750 couples, 8 countries and 12 sites Boston, Rio de Janeiro, Blantyre, Lilongwe, Harare, Pune, Chennai, Chiang Mai Randomization Immediate ART cells/µl AZT+3TC+EFV/ATV Deferred ART CD4 < Endpoints: i) Transmission events ii) OIs and clinical events-who 2, 3, 4 (Tb) iii) ART toxicity
14 HPTN 065 TNT-Plus Test and treat in the USA Evaluate the feasibility and effectiveness of four components of a community-focused enhanced HIV TNT-Plus strategy in the Bronx and in Washington DC: Expand HIV testing Strengthen the link with care for prompt ART initiation (site randomization) Promote adherence to maximize viral suppression (site randomization) Decrease high-risk sex behaviors (prevention for positives) (individual randomization)
15 Seek, test and treat: addressing HIV in the criminal justice system in the USA National Institute of Drug Abuse (NIDA) RFA recently published
16
17 A cluster-randomized trial of the preventive effect of ART - TasP 1 Study hypothesis: Treatment of all HIV-infected individuals regardless of CD4 cell count or viral load in a population will lower HIV incidence in this community (population effectiveness) QuickTime et un décompresseur TIFF (non compressé) sont requis pour visionner cette image.
18 Outcomes of the TasP 1 trial Primary outcome: HIV incidence Other outcomes: HIV-related morbidity (importantly TB) Adherence/compliance Adverse events Behavioural patterns Impact on the community
19 Population effect of Anti-retroviral therapy to Reduce HIV Transmission (PopART) A community cluster-randomized trial in preparation
20 Phase III: Just do it With the best possible monitoring and evaluation of all biomedical, behavioural and psycho-social consequences
21 STOP HIV & AIDS STOP HIV & AIDS: Seek and Treat to Optimally Prevent HIV & AIDS* Prospectively Evaluate the Impact of HAART Expansion on AIDS Morbidity and Mortality and HIV Incidence in British Columbia Intervention Primary Endpoint HAART Expansion HIV Incidence within medical guidelines at years 3 to 5 Secondary Endpoints: Morbidity and mortality, CD4 counts, HIV-1-RNA levels, viral resistance, adverse events, safety, adherence, hospitalization, resource utilization * Supported by the National Institute for Drug Abuse (NIDA) at the NIH
22 ART FOR ART PREVENTION as of November 2009 Concluding remarks - A lot to be learnt from feasibility studies and pilot projects throughout the world - - -
23 ART FOR ART PREVENTION as of November 2009 Concluding remarks - A lot to be learnt from feasibility studies and pilot projects throughout the world - Randomized trials are unavoidable to obtain high-level evidence at population level - -
24 ART FOR ART PREVENTION as of November 2009 Concluding remarks - A lot to be learnt from feasibility studies and pilot projects throughout the world - Randomized trials are unavoidable to obtain high-level evidence at population level - Combining skills in clinical and behavioral research -
25 ART FOR ART PREVENTION as of November 2009 Concluding remarks - A lot to be learnt from feasibility studies and pilot projects throughout the world - Randomized trials are unavoidable to obtain high-level evidence at population level - Combining skills in clinical and behavioral research - Combining agendas of research agencies, implementers, MOH and communities
26
HPTN 052. Myron S. Cohen, MD Principal Investigator. Presented at the 6 th Int. Workshop on HIV Transmission, July 2011, Rome, Italy
HPTN 052 Myron S. Cohen, MD Principal Investigator Presented at the 6 th Int. Workshop on HIV Transmission, 14 15 July 2011, Rome, Italy Antiviral Treatment as Prevention Extensive biological plausibility
More informationHIV : Test and Treat?
HIV : Test and Treat? 14 th HIV Resistance Meeting 22.9.10 Why now? Test and Treat What does it mean? Could it work-what is the evidence? What are the challenges? 1 Universal ART Access 2008 UNAIDS 33
More informationCommunity-Based TasP Trials: Updates and Projected Contributions. Reaching the target: Lessons from HPTN 071 (PopART) Sarah Fidler
Community-Based TasP Trials: Updates and Projected Contributions Reaching the 90-90-90 target: Lessons from HPTN 071 (PopART) Sarah Fidler Cascade of Care: Sub-Saharan Africa HIV test +ve in past 12 m
More informationCombination HIV Prevention
Combination HIV Prevention Timothy Mastro, MD, FACP, DTM&H FHI 360, Durham, North Carolina, USA 7 th INTEREST Workshop, Dakar, Senegal 15 May 2013 Outline What Works for HIV Prevention? Highly Active
More informationTreatment as Prevention:
Treatment as Prevention: HAART Expansion - A Powerful Strategy to Reduce AIDS Morbidity and Mortality and HIV Incidence Julio Montaner MD, FRCPC, FCCP Director, BC-Centre for Excellence on HIV/AIDS, Providence
More informationJulio Montaner MD, DSc(hon), FRCPC, FCCP, FRSC, OBC
Julio Montaner MD, DSc(hon), FRCPC, FCCP, FRSC, OBC Director, BC-Centre for Excellence in HIV/AIDS, Providence Health Care Professor of Medicine and Head, Division of AIDS, University of British Columbia
More informationPsychosocial Issues in ART and HIV Prevention. Steven A. Safren, PhD
Psychosocial Issues in ART and HIV Prevention Steven A. Safren, PhD MSM, Mental Health, and Sexual Health 1. Why is behavioral science important when using ART as prevention? 2. How can we address the
More informationStrategic use of antiretroviral drugs to prevent HIV transmission
Strategic use of antiretroviral drugs to prevent HIV transmission 22th Tunisian Congress of Infectious Diseases 2nd Congress of Federation of Arab Societies of Clinical Microbiology and Infectious Diseases
More informationPREVENTION OF HIV-1 Infection. Myron S. Cohen, MD Institute for Global Health The University of North Carolina
PREVENTION OF HIV-1 Infection Myron S. Cohen, MD Institute for Global Health The University of North Carolina University of North Carolina 6/3/2012 Telling A Story A beginning A middle We ABSOLUTELTY don
More informationHPTN 071 (PopART) Population Effects of Antiretroviral Therapy to Reduce HIV Transmission
HPTN 071 (PopART) Population Effects of Antiretroviral Therapy to Reduce HIV Transmission TWEET LIVE #HPTN071 DIAL IN NUMBER FOR AUDIO: 1-866-740-1260 BROADCAST AUDIO CODE: 4011527 PLEASE USE THE CHAT
More informationBiomedical Prevention in HIV
Biomedical Prevention in HIV CHART - CCAS-CDC 3 RD Joint Meeting Montego Bay, Jamaica August 21-26,2011 Presented by Tina Hylton-Kong, ERTU-CHART Some Slides from Impact of ART on HIV Transmission Wafaa
More informationTreatment as Prevention
Treatment as Prevention The Key to an AIDS-Free Generation Julio Montaner MD, DSc(hon), FRCPC, FCCP, FRSC, OBC Director, BC-Centre for Excellence in HIV/AIDS, Providence Health Care Professor of Medicine
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationEpidemic to Endemic: The Economic Impact of HIV/AIDS
Understanding the Economics of Microbial Threats Epidemic to Endemic: The Economic Impact of HIV/AIDS Katharina Hauck Forum on Microbial Threats Workshop on Understanding the Economics of Microbial Threats
More informationTreatment as Prevention
Optimizing the Impact of ART Treatment as Prevention A Made-in-BC Strategy to End the AIDS Pandemic Julio Montaner, OC, OBC, MD Professor of Medicine and Head, Division of AIDS, University of British Columbia
More informationWorking to End the HIV Pandemic: Glimmers of Hope. Transmission of HIV-1 Biological Requirements
Working to End the HIV Pandemic: Glimmers of Hope Myron S. Cohen, MD Director, Institute for Global Health The University of North Carolina Transmission of HIV-1 Biological Requirements Infectious Inoculum
More informationTasP - Individual versus Public Health Benefit versus Both.
Site Map l Contact Us l Calendar l Join AVAC Donate TasP - Individual versus Public Health Benefit versus Both. Kevin Fisher Policy Director, AVAC June 2012 Multiple choice answer: all of the above We
More informationHIV Prevention. Recent Advances and Implications for the Caribbean
HIV Prevention Recent Advances and Implications for the Caribbean Chris Behrens, MD CCAS/CHART Conference Barbados, August 2010 Cases 200 180 160 140 120 100 80 60 40 20 0 Year HIV Cases AIDS Cases HIV
More informationMale involvement in HIV Prevention Trials
Male involvement in HIV Prevention Trials Examples from HPTN071 Helen Ayles London School of Hygiene and Tropical Medicine Zambart, Lusaka, Zambia Introduction Equity is the absence of avoidable or remediable
More informationART for prevention the task ahead
ART for prevention the task ahead Dr Teguest Guerma WHO/HQS WHO's role and vision Status of the epidemic Overview Progress and challenges in treatment and prevention scale up ART for prevention Questions
More informationTo provide you with the basic concepts of HIV prevention using HIV rapid tests combined with counselling.
Module 2 Integration of HIV Rapid Testing in HIV Prevention and Treatment Programs Purpose Pre-requisite Modules Learning Objectives To provide you with the basic concepts of HIV prevention using HIV rapid
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More informationGNP+ Position Paper. ART for Prevention
GNP+ Position Paper ART for Prevention 18 July 2012 0 Contents GNP+ positions... 2 Introduction... 4 The science: what we know and do not know... 4 ART can reduce the risk of HIV transmission... 4 Unanswered
More informationFrom Africa to Georgia: What We Have Learned From the Treatment for All Initiative
From Africa to Georgia: What We Have Learned From the 90-90-90 Treatment for All Initiative Carlos del Rio, MD Professor of Global Health Rollins School of Public Health Professor of Medicine Emory University
More informationMobility in Africa: human rights and the HIV care cascade
Population Mobility: Challenges for Universal HIV Testing and Treatment Mobility in Africa: human rights and the HIV care cascade Joseph Larmarange Institut de Recherche pour le Développement (IRD) Preliminary
More informationTerapia come prevenzione e ruolo del community viral load (CVR) Andrea Antinori INMI L. Spallanzani IRCCS, Roma
Terapia come prevenzione e ruolo del community viral load (CVR) Andrea Antinori INMI L. Spallanzani IRCCS, Roma Transmission Rate per 100 Person-Yrs ART for HIV Prevention: The Hypothesis The quantity
More informationLearning from the past: How prepared are we for future HIV vaccine efficacy trials in Uganda
Learning from the past: How prepared are we for future HIV vaccine efficacy trials in Uganda Pontiano Kaleebu MRC-UVRI Uganda Research Unit on AIDS & UVRI-IAVI HIV Vaccine Programme Past 1987 Cohort studies
More informationCombination prevention: Public health and human rights imperatives
Combination prevention: Public health and human rights imperatives Gottfried Hirnschall, MD MPH HIV/AIDS Department WHO, Geneva London, June 11, 2012 Outline The epidemic and response What is combination
More informationImplementing interventions targeted at discordant couples: a feasibility analysis for 14 African countries
Implementing interventions targeted at discordant couples: a feasibility analysis for 14 African countries Brian J. Coburn and Sally Blower Center for Biomedical Modeling Semel Institute for Neuroscience
More informationThe Open Label Trial Past and Present
The Open Label Trial Past and Present Jared Baeten, M.D., Ph.D. University of Washington Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine ring for HIV prevention in
More informationThe Financial Implications of Reaching Global Treatment and Prevention Goals CHAI slide warehouse
The Financial Implications of Reaching Global Treatment and Prevention Goals CHAI slide warehouse Clinton Health Access Initiative (CHAI) October 2, 2015 As we near global consensus toward test and offer
More informationThe Open Label Trial Past and Present
The Open Label Trial Past and Present Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine ring for HIV prevention
More informationState of the Art for ART for Prevention. Wafaa El-Sadr, MD, MPH ICAP-Columbia University
State of the Art for ART for Prevention Wafaa El-Sadr, MD, MPH ICAP-Columbia University Millions Global Scale-Up of HIV Treatment 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 End of 2002 End of 2003 End of 2004
More informationincreased efficiency. 27, 20
Table S1. Summary of the evidence on the determinants of costs and efficiency in economies of scale (n=40) a. ECONOMETRIC STUDIES (n=9) Antiretroviral therapy (n=2) Scale was found to explain 48.4% of
More informationProfessor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA
17 TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION (BHIVA) Professor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA 6-8 April 2011, Bournemouth International Centre 17 TH ANNUAL
More informationWhen PrEP fails. Laura Waters MD FRCP Mortimer Market Centre London
When PrEP fails Laura Waters MD FRCP Mortimer Market Centre London www.aidsunited.org PrEP works If people at risk take it If it s taken in the right way If it s available Commissioned/licensed Affordable
More informationDownloaded from:
Hayes, R; Fidler, S; Cori, A; Fraser, C; Floyd, S; Ayles, H; Beyers, N; El-Sadr, W; HPTN 071 (PopART) Study Team (2015) HIV Treatment-As-Prevention Research: Taking the Right Road at the Crossroads. PLoS
More informationTreat All : From Policy to Action - What will it take?
Strategy Finance Integration Cascade of services People centred Political Will Treat All : From Policy to Action - What will it take? Thursday, 9 June, 13.00 14.30 Conference Room 11, United Nations Questions
More informationHIV & AIDS IN SOUTH AFRICA: WHERE ARE WE AND WHAT ARE
HIV & AIDS IN SOUTH AFRICA: WHERE ARE WE AND WHAT ARE THE REMAINING CHALLENGES DR YOGAN PILLAY, NDOH SA HIV CLINICIANS SOCIETY CONFERENCE, CAPE TOWN 25 NOVEMBER, 2012 GLOBAL DATA 34m people living with
More informationFinancial Incentives, Linkage to Care and Viral Suppression HPTN 065 (TLC-Plus) Study. Wafaa El-Sadr ICAP at Columbia University New York, NY
Financial Incentives, Linkage to Care and Viral Suppression HPTN 065 (TLC-Plus) Study Wafaa El-Sadr ICAP at Columbia University New York, NY Outline of Presentation Background and study rationale Methods
More information1. Africa Centre for Health and Population Studies 2. London School of Hygiene and Tropical Medicine 3. University College London
A systematic review of the effects of interrupted antiretroviral interventions for prevention of mother-to-child transmission of HIV on maternal disease progression and survival Naidu KK 1, Mori R 2, Newell
More informationBiomedical HIV Prevention & TaP Treatment as Prevention 2013
Biomedical HIV Prevention & TaP Treatment as Prevention 2013 Community Education Team The AIDS Institute/AIDS Alliance Be the Generation to End the AIDS Epidemic bethegeneration.nih.gov www.aids-alliance.org/education/vaccine
More informationHIV Treatment as Prevention (TasP)
HIV Treatment as Prevention (TasP) Last updated: April 3, 2019 Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is Treatment as Prevention?
More informationMarginalized Groups as Agents of Change in HIV and AIDS: YOPAD - a story from Dar es salaam Tanzania
XVI INTERNATIONAL AIDS CONFERENCE TORONTO - CANADA 13 TH 18 TH AUGUST 2006 Marginalized Groups as Agents of Change in HIV and AIDS: YOPAD - a story from Dar es salaam Tanzania PASADA Presenter: Mary Ash
More informationCombination HIV Prevention Research Carl W. Dieffenbach, Ph.D.
Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH October 13, 2011 Multiple strategies needed to assemble a wellrounded prevention toolkit Know the epidemics
More informationThe Feasibility of HIV Prevention Cohort Studies among Men who have Sex with Men (MSM) in sub-saharan Africa
The Feasibility of HIV Prevention Cohort Studies among Men who have Sex with Men (MSM) in sub-saharan Africa HPTN 075 Protocol Chair: Theo Sandfort New York State Psychiatric Institute and Columbia University
More informationMTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012
MTN-020 Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012 MTN-020 / ASPIRE A Multi-Center, Randomized, Double- Blind, Placebo-Controlled
More informationTreatment as Prevention in India: What will it take?
Treatment as Prevention in India: What will it take? Suniti Solomon, MD FAMS Director, YRGCARE August 26, 2011 ICAAP 10, Busan, South Korea HIV IN INDIA The First Evidence The Numbers.. Source: NACO Prevalence
More informationImpact of the Proposed Cuts to HIV/AIDS Research. Kevin Fisher AVAC September 7, 2017
Impact of the Proposed Cuts to HIV/AIDS Research Kevin Fisher AVAC September 7, 2017 President s FY18 Budget Cuts $544 m from the FY 2017 NIH HIV/AIDS research budget levels A cut of 18.5% FY 18 Cut FY
More informationUnderstanding the Results of VOICE
CONTACT: Lisa Rossi +1-412- 916-3315 (mobile) or +27-(0)73-323-0087 (through 7 March) rossil@upmc.edu About VOICE Understanding the Results of VOICE VOICE Vaginal and Oral Interventions to Control the
More informationHIV/AIDS-Related Communication and Prior HIV Testing in Tanzania, South Africa, Zimbabwe, and Thailand
HIV/AIDS-Related Communication and Prior HIV Testing in Tanzania, South Africa, Zimbabwe, and Thailand Ellen Setsuko Hendriksen 1, Daniel Hbulinka 2, Suwat Chariyalertsak 3 Alfred Chingono 4, Glenda Gray
More informationUsing anti-hiv drugs for prevention
Using anti-hiv drugs for prevention Highlights from AIDS 2012 (and 2 nd International Workshops on Treatment as Prevention) Tim Rogers, trogers@catie.ca Using anti-hiv Drugs for Prevention Outline Treatment
More informationElimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014
Elimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014 Outline Background History of prevention of mother to child
More informationHIV/AIDS and Nutrition Programming in ACF International Network
HIV/AIDS and Nutrition Programming in ACF International Network Main Aim of ACF-International (ACFIN) To combat malnutrition through assistance in: Nutrition Health Water and Sanitation Food Security Advocacy
More informationThe population impacts of ART scale-up in rural KwaZulu-Natal, South Africa: Findings from the Africa Centre s population cohort
The population impacts of ART scale-up in rural KwaZulu-Natal, South Africa: Findings from the Africa Centre s population cohort Frank Tanser Presentation at the South African Clinicians Society Conference
More informationHow has the Polio Eradication Initiative influenced the global AIDS response? Bradley S. Hersh, MD, MPH
How has the Polio Eradication Initiative influenced the global AIDS response? Bradley S. Hersh, MD, MPH Presentation Outline Big history of global HIV epidemic Current status of HIV and the global AIDS
More informationThe potential impact of partially effective HIV prevention strategies: Insights from mathematical modeling analyses
Click to edit Master title style Click to edit Master title style The potential impact of partially effective HIV prevention strategies: Insights from mathematical modeling analyses Ruanne V. Barnabas,
More informationHIV status and fertility desires, contraceptive use, and pregnancy rates in Rakai, Uganda
HIV status and fertility desires, contraceptive use, and pregnancy rates in Rakai, Uganda Fredrick Makumbi, PhD School of Public Health, Makerere University, and Rakai Health Sciences Program A presentation
More informationART and Transmission. Martin Fisher. Brighton and Sussex University Hospitals, UK
ART and Transmission Martin Fisher Brighton and Sussex University Hospitals, UK 11th Advanced HIV Course Aix-en-Provence 2013 New HIV diagnoses by exposure group: United Kingdom, 2002 2011 1 Predicted
More informationA PAPER ON; EMPOWERMENT LEARNING STRATEGIES ON HIV/AIDS PREVENTION: THE CASE OF UGANDA
The Republic of Uganda A PAPER ON; EMPOWERMENT LEARNING STRATEGIES ON HIV/AIDS PREVENTION: THE CASE OF UGANDA By Hon: Bakoko Bakoru Zoë Minister of Gender, Labour and Social Development in The Republic
More informationLIMPOPO PROVINCIAL MEN S SECTORS/BROTHERS FOR LIFE
LIMPOPO PROVINCIAL MEN S SECTORS/BROTHERS FOR LIFE PRESENTED BY: RAPAKWANA JOHANNAH MANAGER:GAAP in HIV & AIDS & STIs Directorate DEPT OF HEALTH AND SOCIAL DEVELOPMENT VENUE: THE RANCH HOTEL DATE:09.03.2010
More informationEnding The HIV/AIDS Epidemic in America
Ending The HIV/AIDS Epidemic in America Unique Moment in History Media inquiries: Matt Matassa 703.647.1909; mmatassa@fhi.org FOR IMMEDIATE RELEASE: Thursday, 12 May 2011, 11 am EST Initiation of Antiretroviral
More informationBUDGET AND RESOURCE ALLOCATION MATRIX
Strategic Direction/Function ILO Strengthened capacity of young people, youth-led organizations, key service providers and partners to develop, implement, monitor and evaluate HIV prevention programmes
More informationThresia Sebastian MD, MPH University of Colorado, Denver Global Health Disasters Course October 2016
Thresia Sebastian MD, MPH University of Colorado, Denver Global Health Disasters Course October 2016 1 Objectives of today s lecture Describe global goals in the fight against HIV Review the epidemiology
More informationETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF
ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF PrEP MTN Regional Meeting Cape Town 20 September 2017 Dhevium Govender South African Medical Research Council HIV Prevention Research Unit Quality/Regulatory
More informationTreatment as prevention (TasP) Can treatment reduce the transmission of HIV: Experience from the UK
Treatment as prevention (TasP) Can treatment reduce the transmission of HIV: Experience from the UK Dr Valerie Delpech Health Protection Agency, London (Public Health England) Outline! Brief overview Science,
More informationSUMMARY OF CHANGES INCLUDED IN THE FULL PROTOCOL AMENDMENT OF:
SUMMARY OF CHANGES INCLUDED IN THE FULL PROTOCOL AMENDMENT OF: HPTN 071: Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART): A cluster-randomized trial of the impact of a
More informationC R E A E. Consortium to Respond Effectively to the AIDS-TB Epidemic. An International Research Partnership
C R E A E Consortium to Respond Effectively to the AIDS-TB Epidemic An International Research Partnership Supported by the Bill and Melinda Gates Foundation http://www.tbhiv-create.org Overview What is
More informationStigma and HIV. Maria E. Alvarez, MPA. LEAD PUBLIC HEALTH ADVISOR Team Lead, Capacity Building Branch Partnerships Team
Stigma and HIV Maria E. Alvarez, MPA LEAD PUBLIC HEALTH ADVISOR Team Lead, Capacity Building Branch Partnerships Team 3 rd Annual International Conference on Stigma Howard University Blackburn Center Washington
More informationhiv/aids Programme programmatic update Antiretroviral Treatment as Prevention (TasP)
hiv/aids Programme programmatic update Antiretroviral Treatment as Prevention (TasP) of HIV and TB june 2012 Antiretroviral Treatment as Prevention (TasP) of HIV and TB: 2012 update WHO/HIV/2012.12 World
More informationModule 2: Integration of HIV Rapid Testing in HIV Prevention and Treatment Programs
Module 2: Integration of HIV Rapid Testing in HIV Prevention and Treatment Programs Purpose Pre-requisite Modules Module Time Learning Objectives To provide the participants with the basic concepts of
More informationDEPARTMENT OF HEALTH RESPONSE TO KEY POPULATIONS
DEPARTMENT OF HEALTH RESPONSE TO KEY POPULATIONS KEY POPULATIONS PREVENTION INTERVENTIONS Ms E Marumo HIV PREVENTION STRATEGIES 13 June 2017 1 Background SA has about 7.1 million people living with HIV
More informationPrevention and Treatment of HIV/AIDS among Drug Using Populations: NIDA s Research Priorities
Prevention and Treatment of HIV/AIDS among Drug Using Populations: NIDA s Research Priorities Jacques Normand, Ph.D. Director, AIDS Research Program NIDA/NIH Objectives Briefly Characterize the magnitude
More informationTrends in HIV prevalence and incidence sex ratios in ALPHA demographic surveillance sites,
Trends in HIV prevalence and incidence sex ratios in ALPHA demographic surveillance sites, 1990 2010 Zaba B 1, Calvert C 1, Marston M 1, Isingo R 2, Nakiyingi Miiro J 3, Lutalo T 4, Crampin A 1,5, Nyamukapa
More informationImportance of Viral Suppression to Reduce HIV Transmission: Recent Evidence
Importance of Viral Suppression to Reduce HIV Transmission: Recent Evidence Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine Viral suppression
More informationhiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants
hiv/aids Programme Programmatic update Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants EXECUTIVE SUMMARY April 2012 EXECUTIVE SUMMARY Recent developments
More informationCommunity engagement in HPTN 071 (PopART) trial: lessons learnt from implementing a novel data collection Technique photo-journal
Community engagement in HPTN 071 (PopART) trial: lessons learnt from implementing a novel data collection Technique photo-journal JABULILE BALENI, ANGELIQUE THOMAS, NOZIZWE MAKOLA, MUSONDA SIMWINGA AND
More informationHIV in KwaZulu-Natal and the ANRS Treatment as Prevention Trial
HIV in KwaZulu-Natal and the ANRS Treatment as Prevention Trial Deenan Pillay Director, Africa Centre for Population Health, UKZN Professor of Virology, UCL Africa Centre for Population Health Spatial
More informationSupplementary Online Content
Supplementary Online Content El-Sadr WM, Donnell D, Beauchamp G, et al. Financial incentives for linkage to care and viral suppression among HIV-positive patients: a randomized clinical trial (HPTN 065)
More informationDr Ade Fakoya Senior HIV Advisor
Strengthening community systems to support families, communities and health facilities to prevent parent-to-child transmission and improve the health of women and children Dr Ade Fakoya Senior HIV Advisor
More informationOverview of Paediatric HIV Treatment and Prevention: From Then to Now. Peter Mugyenyi, Joint Clinical Research Centre Kampala, Uganda
Overview of Paediatric HIV Treatment and Prevention: From Then to Now Peter Mugyenyi, Joint Clinical Research Centre Kampala, Uganda Outline The plight of HIV infected children (1980s and 1990s) Trends
More informationWHAT IS STAR? MALAWI ZAMBIA ZIMBABWE SOUTH AFRICA
UNITAID PSI WHAT IS STAR? The UNITAID/PSI HIV Self-Testing Africa (STAR) Project is a four-year initiative to catalyze the market for HIV self-testing (HIVST). The project will be implemented in two phases,
More informationUpdate on PMTCT. African Health Profession Regulatory Collaborative for Nurses and Midwives. Johannesburg, Republic of South Africa, June 18-22, 2012
PMTCT Update Update on PMTCT Margarett Davis, MD, MPH Chief, Maternal and Child Health Branch Division of Global HIV/AIDS Centers for Disease Control and Prevention (CDC) African Health Profession Regulatory
More informationROUGH GUIDE TO EHPSA RESEARCH
RRIF Funded Research Studies Aids and Society Research Unit (ASRU), University of Cape Town, Dr Rebecca Hodes Co-Principal Investigator Elona Toska University of Oxford Lucie Cluver: (Coprincipal Investigator)
More informationEnding the AIDS epidemic: Science, Policy and Community. Peter Godfrey-Faussett, UNESCO Merck Africa Research Summit 19/10/2015
Ending the AIDS epidemic: Science, Policy and Community Peter Godfrey-Faussett, UNESCO Merck Africa Research Summit 19/10/2015 The cooking pot sits on three stones Science Policy Community Science 20 May
More informationEnrollment of high risk men in Africa
Enrollment of high risk men in Africa Susan Allen MD MPH Professor, Department of Pathology and Laboratory Medicine Emory University Rwanda Zambia HIV Research Group Africa Population 950 million by Region
More informationHIV Drug Resistance Regional Update Eastern & Southern African Region
HIV Drug Resistance Regional Update Eastern & Southern African Region Dr R Banda, IST/ESA Dr F Cham, IST/ESA Dr RG Vaz, WHO AFRO HIVDR Steering Committee Meeting, Geneva 11-12 November 2009 1 Presentation
More informationAntiretrovirals for HIV prevention:
Antiretrovirals for HIV prevention: Topical PrEP, Systemic PrEP and Treatment for Prevention Presentation at 6th International workshop on HIV treatment, pathogenesis and prevention research in resource-limited
More informationInnovative Approaches for Eliminating Mother-to-Child Transmission of HIV
Innovative Approaches for Eliminating Mother-to-Child Transmission of HIV Community Mentor Mothers: Empowering Clients Through Peer Support A Spotlight on Malawi COMMUNITY MENTOR MOTHERS 1 Optimizing HIV
More informationHIV Drug Resistance Surveillance and Monitoring in the Southeast Asia Region
HIV Drug Resistance Surveillance and Monitoring in the Southeast Asia Region Padmini Srikantiah, MD MPH HIV/AIDS Unit WHO- Regional Office for Southeast Asia The HIV epidemic in Southeast Asia Estimated
More informationBiomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013
Biomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013 Community Education Team The AIDS Institute/AIDS Alliance Be the Generation to End the AIDS Epidemic bethegeneration.nih.gov www.aids-alliance.org/education/vaccine
More informationArticles. Copyright Coates et al. Open Access article distributed under the terms of CC BY.
Effect of community-based voluntary counselling and testing on HIV incidence and social and behavioural outcomes (NIMH Project Accept; HPTN 043): a cluster-randomised trial Thomas J Coates, Michal Kulich,
More informationGLOBAL AIDS MONITORING REPORT
KINGDOM OF SAUDI ARABIA MINISTRY OF HEALTH GLOBAL AIDS MONITORING REPORT COUNTRY PROGRESS REPORT 2017 KINGDOM OF SAUDI ARABIA Submission date: March 29, 2018 1 Overview The Global AIDS Monitoring 2017
More informationImmunologic and Virologic Disease Progression and Response to ART Across Geographic Regions: Outcomes from HPTN 052
Immunologic and Virologic Disease Progression and Response to ART Across Geographic Regions: Outcomes from HPTN 052 Mina C. Hosseinipour, MD, MPH Site Investigator UNC Project, Lilongwe, Malawi UNC School
More informationSecond generation HIV surveillance: Better data for decision making
Second generation HIV surveillance: Better data for decision making Prof Thomas M Rehle, MD, PhD Human Sciences Research Council, South Africa HAI Conference on Prevention and Control of the HIV Epidemic
More informationhiv/aids Programme meeting report March 2012, Siem Reap, Cambodia Executive Summary
hiv/aids Programme meeting report WHO NIH Informal Consultation on Antiretroviral Treatment as HIV Prevention: Implementation Science in Asia 26-28 March 2012, Siem Reap, Cambodia Executive Summary WHO
More informationAdapting Treatment 2.0 in Viet Nam - Toward Universal and Sustainable Access -
Adapting Treatment 2.0 in Viet Nam - Toward Universal and Sustainable Access - Associate Professor, Bui Duc Duong, MD, Ph.D. Deputy Director General, Ministry of Health Socialist Republic of Viet Nam HIV
More informationUnderstanding Epidemics Section 2: HIV/AIDS
Understanding Epidemics Section 2: HIV/AIDS Worksheet Fill out this worksheet as you work through the material on the website. 1. Give 4 reasons for the lack of accurate data on HIV/AIDS. 1 AIDS is not
More informationA Call to Action Children The missing face of AIDS
A Call to Action Children The missing face of AIDS Scaling up Paediatric HIV Care Treatment in resource limited settings Dr Chewe Luo MMed(Paed); MTropPaed; PhD UNICEF Health Section Programme Division
More informationXVII INTERNATIONAL AIDS CONFERENCE MEXICO CITY, 3-8 August 2008 SCALING-UP NATIONAL PMTCT PROGRAM
XVII INTERNATIONAL AIDS CONFERENCE MEXICO CITY, 3-8 August 2008 SCALING-UP NATIONAL PMTCT PROGRAM Phasing more efficacious ARV regimen for PMTCT in resource limited setting Lessons Learned from RWANDA
More information